01 Aug 2011 - SUCCESSFUL FINANCING ROUND ACCELERATES THE DEVELOPMENT OF PNEUMACARE’S REVOLUTIONARY MEDICAL MONITORING TECHNOLOGY - PneumaCare Limited is pleased to announce that it has completed a successful investment round of £2.0m. The financing was led by new investor Sud Investments, together with a group of existing investors including Cambridge Enterprise, Cambridge Capital Group and members of the Cambridge Angels group.
‘This funding, and the recent CE mark approval for our PneumaScan™ product, puts PneumaCare in a strong position to address the needs of the spirometry and respiratory illness market,’ says Ward Hills, CEO of PneumaCare. ‘It will enable us to accelerate the commercial development of the PneumaScan™ product family, for the benefit of the growing numbers of patients.’
PneumaCare has worked closely with another of its investors, Plextek Ltd, to transform 3D motion capture technology, originally developed for the computer game and film industries, into its lead product. PneumaScan™ uses light to measure and monitor how deeply and how quickly a patient is breathing, and what muscle groups are being used. It achieves the same results as the traditional spirometer but has several advantages, the crucial one being that no physical contact is necessary... PneumaCare's Press Release -
